Generate Biomedicines, a clinical-stage biotech pioneering the use of AI in drug design, has successfully completed its initial public offering (IPO), raising approximately USD 400 million. The company priced 25 million shares at USD 16.00 per share, with the offering managed by Goldman Sachs and Morgan Stanley. The funds are intended to advance the company's lead candidate, GB-0895, through two global Phase III clinical trials for severe asthma, as well as to support ongoing development of its generative biology platform. This IPO marks a significant milestone for the Flagship Pioneering-founded company, which has previously raised substantial funding through private rounds and strategic collaborations with companies like Amgen and Novartis.

Generate's lead asset, GB-0895, is a long-acting anti-TSLP monoclonal antibody (mAb) engineered using the company's proprietary AI platform. The drug is designed to be administered every 6 months, potentially reducing the treatment burden for patients with severe asthma. The upcoming Phase III trials, SOLAIRIA-1 and SOLAIRIA-2, are set to enrol approximately 1,600 patients globally to evaluate the efficacy and safety of GB-0895. The company's platform, which integrates machine learning with high-throughput experimentation, has demonstrated the ability to quickly generate novel protein therapeutics.

PharmCube's NextBiopharm® database lists 16 active projects in Generate's pipeline across seven different areas. Click here to request a free trial for NextBiopharm®.